Venture Capitalists News Hubb
Advertisement Banner
  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact
No Result
View All Result
  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact
No Result
View All Result
Venture Capitalists News Hubb
No Result
View All Result
Home Venture Capital Market

The Capital Quest | Israel’s Amenity Analytics gets US buyer; Nectin extends Series A

admin by admin
December 1, 2022
in Venture Capital Market


Israeli startup Amenity Analytics, which develops natural language processing data, has been acquired by US-based fintech firm Symphony for an undisclosed amount.

All the 50 Amenity employees will join Symphony as part of the deal.

Amenity has raised $40 million over the last seven years that it has been in existence and has offices in the US and Israel. It is backed by the likes of American insurer Starr International Company, Allstate, Intel Capital, and State of Mind Ventures.

Amenity was founded in 2015 by chief executive officer Nathaniel Storch and Ronen and Hedva Feldman, who are no longer active in the company.

Symphony develops a markets’ infrastructure and technology platform, where solutions are built or integrated to standardize, automate and innovate financial services workflows.

Nectin Therapeutics

Israeli biotech company Nectin Therapeutics has extended its Series A funding round to more than $25 million.

Nectin, which develops novel targeted immunotherapies to address resistance to approved immuno-oncology treatments, was backed in the round by IBF and Peregrine Ventures, which led the funding round.

The two lead investors were joined in the round by aMoon Fund and other existing investors.

Nectin said it will use the new money to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs).

The funding also comes even as the company has begun closing of the first patient in its Phase 1 clinical trial of NTX1088, its first-in-class PVR (CD155) blocker, in cancer patients with locally advanced and metastatic solid tumors.

“Nectin has developed a highly innovative pipeline that has the potential to fundamentally overcome the limitations of existing IO therapies, delivering new treatment options for patients suffering from difficult-to-treat cancers, and we look forward to the results of the Phase 1 clinical trial of NTX1088,” said Fabian Tenenbaum, CEO at Nectin.

Related



Source link

Previous Post

Binance Seizes FTX Bankruptcy To Expand Into Japan — Again

Next Post

Where is the Metaverse headed in 2023?

Next Post

Where is the Metaverse headed in 2023?

Recommended

Government gives official recognition to Esports

1 month ago

New Venture Offers Ethereum Staking Yields With Limited Downside

2 months ago

Edtech unicorn Vedantu’s losses widen to Rs 696 Cr in FY22

1 week ago

FTX May Need To Claw Back $100M From 1,500 Bahamian FTX Accounts

2 months ago

Asia, Africa and LatAm set to get $425-mn energy-focused fund-of-funds

2 months ago

Late Queen Elizabeth II Sparks Influx of Meme Coins and NFTs

5 months ago

© 2022 Venture CapitaLists News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact

© 2022 Venture Capitalists News Hubb All rights reserved.